Provided by Tiger Trade Technology Pte. Ltd.

Alzamend Neuro, Inc

1.83
-0.0600-3.17%
Post-market: 1.77-0.0564-3.08%19:35 EDT
Volume:123.53K
Turnover:222.99K
Market Cap:6.96M
PE:-0.40
High:1.88
Open:1.85
Low:1.71
Close:1.89
52wk High:10.17
52wk Low:1.58
Shares:3.80M
Float Shares:3.78M
Volume Ratio:0.43
T/O Rate:3.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5891
EPS(LYR):-11.3245
ROE:-249.97%
ROA:-107.01%
PB:3.18
PE(LYR):-0.16

Loading ...

Alzamend Neuro faces Nasdaq delisting risk as stockholders’ equity falls to 2.2 million USD

Reuters
·
6 hours ago

BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital

Reuters
·
Mar 16

Alzamend Neuro Inc reports results for the quarter ended January 31 - Earnings Summary

Reuters
·
Mar 12

Alzamend Neuro Q3 net loss widens 112% to USD 2.2 million

Reuters
·
Mar 12

Alzamend Neuro Establishes ATM Equity Offering Agreement

TIPRANKS
·
Mar 07

BRIEF-Alzamend Neuro Inc - Enters ATM Sales Agreement To Sell Up To $3.0 Million In Common Stock - SEC Filing

Reuters
·
Mar 07

Alzamend Neuro Inc - Enters Atm Sales Agreement to Sell up to $3.0 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Mar 07

Alzamend Neuro Inc expected to post a loss of $1.92 a share - Earnings Preview

Reuters
·
Mar 07

Alzamend Neuro Inc. Announces Date for 2026 Annual Meeting of Stockholders

Reuters
·
Feb 10

Director Milton C. Ault III Reports Sale of Alzamend Neuro Inc. Common Shares

Reuters
·
Dec 31, 2025

Director William B. Horne Reports Disposal of Alzamend Neuro Inc. Common Shares

Reuters
·
Dec 24, 2025

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 22, 2025

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025

Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate

Benzinga
·
Dec 10, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

Reuters
·
Nov 20, 2025

BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study Conducted At Massachusetts General Hospital

Reuters
·
Nov 19, 2025

BUZZ-Alzamend rises after completing mid-stage brain lithium study

Reuters
·
Nov 19, 2025

Alzamend Neuro Announces Completion of Clinical Portion of Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

THOMSON REUTERS
·
Nov 19, 2025

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Benzinga
·
Nov 19, 2025

Alzamend Neuro Mourns Loss of Director Andrew Woo

TIPRANKS
·
Nov 19, 2025